173 related articles for article (PubMed ID: 24664955)
1. A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.
Fouladi M; Perentesis JP; Phillips CL; Leary S; Reid JM; McGovern RM; Ingle AM; Ahern CH; Ames MM; Houghton P; Doyle LA; Weigel B; Blaney SM
Pediatr Blood Cancer; 2014 Jul; 61(7):1246-51. PubMed ID: 24664955
[TBL] [Abstract][Full Text] [Related]
2. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Yap TA; Yan L; Patnaik A; Fearen I; Olmos D; Papadopoulos K; Baird RD; Delgado L; Taylor A; Lupinacci L; Riisnaes R; Pope LL; Heaton SP; Thomas G; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
J Clin Oncol; 2011 Dec; 29(35):4688-95. PubMed ID: 22025163
[TBL] [Abstract][Full Text] [Related]
3. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Yap TA; Yan L; Patnaik A; Tunariu N; Biondo A; Fearen I; Papadopoulos KP; Olmos D; Baird R; Delgado L; Tetteh E; Beckman RA; Lupinacci L; Riisnaes R; Decordova S; Heaton SP; Swales K; deSouza NM; Leach MO; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
Clin Cancer Res; 2014 Nov; 20(22):5672-85. PubMed ID: 25239610
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).
Cash T; Fox E; Liu X; Minard CG; Reid JM; Scheck AC; Weigel BJ; Wetmore C
Pediatr Blood Cancer; 2021 Sep; 68(9):e29065. PubMed ID: 33881209
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.
Hudis C; Swanton C; Janjigian YY; Lee R; Sutherland S; Lehman R; Chandarlapaty S; Hamilton N; Gajria D; Knowles J; Shah J; Shannon K; Tetteh E; Sullivan DM; Moreno C; Yan L; Han HS
Breast Cancer Res; 2013 Nov; 15(6):R110. PubMed ID: 24252402
[TBL] [Abstract][Full Text] [Related]
7. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.
Spunt SL; Grupp SA; Vik TA; Santana VM; Greenblatt DJ; Clancy J; Berkenblit A; Krygowski M; Ananthakrishnan R; Boni JP; Gilbertson RJ
J Clin Oncol; 2011 Jul; 29(21):2933-40. PubMed ID: 21690471
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
10. A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children's Oncology Group phase 1 and pilot consortium trial (ADVL1315).
Geller JI; Fox E; Turpin BK; Goldstein SL; Liu X; Minard CG; Kudgus RA; Reid JM; Berg SL; Weigel BJ
Cancer; 2018 Dec; 124(23):4548-4555. PubMed ID: 30394521
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).
Bukowinski A; Chang B; Reid JM; Liu X; Minard CG; Trepel JB; Lee MJ; Fox E; Weigel BJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28892. PubMed ID: 33438318
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study.
Hoffman LM; Fouladi M; Olson J; Daryani VM; Stewart CF; Wetmore C; Kocak M; Onar-Thomas A; Wagner L; Gururangan S; Packer RJ; Blaney SM; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
Childs Nerv Syst; 2015 Aug; 31(8):1283-9. PubMed ID: 25930724
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.
Doi T; Tamura K; Tanabe Y; Yonemori K; Yoshino T; Fuse N; Kodaira M; Bando H; Noguchi K; Shimamoto T; Ohtsu A
Cancer Chemother Pharmacol; 2015 Aug; 76(2):409-16. PubMed ID: 26104654
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors.
Mehnert JM; Kaveney AD; Malhotra J; Spencer K; Portal D; Goodin S; Tan AR; Aisner J; Moss RA; Lin H; Bertino JR; Gibbon D; Doyle LA; White EP; Stein MN
Cancer Chemother Pharmacol; 2019 Oct; 84(4):899-907. PubMed ID: 31463691
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Chuk MK; Widemann BC; Minard CG; Liu X; Kim A; Bernhardt MB; Kudgus RA; Reid JM; Voss SD; Blaney S; Fox E; Weigel BJ
Pediatr Blood Cancer; 2018 Aug; 65(8):e27077. PubMed ID: 29693796
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA; Thompson PA; Horton TM; Ingle AM; Ahern CH; McGovern RM; Reid JM; Ames MM; Espinoza-Delgado I; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2013 Mar; 60(3):390-5. PubMed ID: 22887890
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity in RAS-driven tumors by blocking AKT and MEK.
Tolcher AW; Khan K; Ong M; Banerji U; Papadimitrakopoulou V; Gandara DR; Patnaik A; Baird RD; Olmos D; Garrett CR; Skolnik JM; Rubin EH; Smith PD; Huang P; Learoyd M; Shannon KA; Morosky A; Tetteh E; Jou YM; Papadopoulos KP; Moreno V; Kaiser B; Yap TA; Yan L; de Bono JS
Clin Cancer Res; 2015 Feb; 21(4):739-48. PubMed ID: 25516890
[TBL] [Abstract][Full Text] [Related]
19. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies.
Gupta S; Argilés G; Munster PN; Hollebecque A; Dajani O; Cheng JD; Wang R; Swift A; Tosolini A; Piha-Paul SA
Clin Cancer Res; 2015 Dec; 21(23):5235-44. PubMed ID: 26187616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]